Top of the morning to you, and a fine one it is. Despite the doom and gloom that may too easily cloud our collective outlooks, we are choosing to look on the sunny side today. After all, why not appreciate the blue skies and cool breezes enveloping the Pharmalot campus? As the Morning Mayor taught us: Every new day should be unwrapped like a precious gift. So while you tug on the ribbon, you can also peruse a few items of interested collected below. Hope your day goes well and, of course, we hope you keep safe. …

White House coronavirus response coordinator Deborah Birx sent an email to senior colleagues saying the way the administration initially distributed supplies of remdesivir should not happen again, according to The Wall Street Journal. In the May 7 email sent to fellow Trump administration task force members and other senior officials, Birx said her colleagues would review how the decision-making led to a “misalignment” of allocation of the experimental Gilead Sciences (GILD) Covid-19 drug in the days after the government began distribution.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy